Načítá se...
Prolonged complete response following gemcitabine-erlotinib combined therapy in advanced pancreatic cancer
Pancreatic cancer is one of the most lethal types of malignant solid tumor and is typically associated with a poor prognosis. The majority of patients are diagnosed with advanced-stage disease, therefore, the median survival period is <6 months. Recently, a number of basic research projects and c...
Uloženo v:
| Vydáno v: | Oncol Lett |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
D.A. Spandidos
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4734067/ https://ncbi.nlm.nih.gov/pubmed/26893699 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2015.4009 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|